SequelSEC

Jade Biosciences, Inc. JBIO

Pharmaceutical Preparations · CIK 0001798749 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$113.54M
Fiscal year ended 2025-12-31
Free cash flow
-$94.88M
Fiscal year ended 2025-12-31

Jade Biosciences, Inc. (JBIO) reported net income of -$127.41M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Jade Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Jade Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$113.54M-$74.60M-$81.41M-$53.24M-$23.02M-$8.89M
Net income-$127.41M-$69.63M-$75.52M-$51.51M-$22.96M-$9.61M
Research & development$93.12M$53.19M$64.22M$38.62M$14.99M$7.94M
Weighted-average diluted sharesshares 31.36Mshares 28.58Mshares 26.33Mshares 24.47Mshares 12.29MUnavailable
Pretax income-$127.35M-$69.57M-$75.46M-$51.49M-$22.96M-$9.61M
Income tax expense$58.00K$55.00K$56.00K$25.00K$3.00KUnavailable
Diluted EPS$-3.19$-2.44$-2.87$-2.10$-1.87Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$20.42M$21.41M$17.19M$14.62M$8.04M$949.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Jade Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$88.44M$69.39M$23.49M$22.40M$54.20M$4.57M
Total assets$349.78M$72.80M$127.42M$135.30M$175.36M$4.72M
Current assets$348.82M$69.65M$124.23M$131.50M$174.33M$4.68M
Total liabilities$17.26M$119.60M$17.96M$8.56M$2.94M$1.77M
Current liabilities$16.54M$12.00M$17.64M$7.78M$2.55M$1.77M
Total equity incl. NCI$332.52M-$46.80M$109.46M$126.74M$172.42M-$13.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.15M$1.29M$2.40M$2.58M$1.21M$618.00K

Cash flow

Jade Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$94.69M-$71.20M-$56.78M-$39.12M-$27.40M-$7.86M
Capital expenditures$196.00KUnavailable$142.00K$195.00K$181.00KUnavailable
Investing cash flow-$247.01M$56.03M$11.88M$6.93M-$113.43MUnavailable
Financing cash flow$360.77M$25.43M$46.00M$396.00K$190.46M$8.92M
Net change in cash$19.05M$10.26M$1.09M-$31.80M$49.62M$1.06M
Stock-based compensation$20.01M$11.31M$11.91M$5.48M$2.04M$58.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Jade Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$94.88MUnavailable-$56.92M-$39.32M-$27.58MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio21.09x5.81x7.04x16.90x68.37x2.64x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-06View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-04-25View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 16285000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.